Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

08:00am, Thursday, 07'th May 2026

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.

Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison

01:12am, Monday, 27'th Apr 2026

Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Cronos Group (NASDAQ: CRON - Get Free Report) are both medical companies, but which is the better investment? We will compare the two compa

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of “Hold” by Analysts

02:21am, Monday, 06'th Apr 2026

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH - Get Free Report) (TSE: AUP) has earned an average recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings r

SG Americas Securities LLC Grows Position in Aurinia Pharmaceuticals Inc $AUPH

04:45am, Sunday, 05'th Apr 2026

SG Americas Securities LLC raised its holdings in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) (TSE: AUP) by 69.6% in the undefined quarter, according to its most recent Form 13F filing with the Securit

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

08:00am, Monday, 30'th Mar 2026

ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value

Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance

04:15pm, Friday, 27'th Mar 2026

Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net p

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

11:00am, Monday, 23'rd Mar 2026

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

10:26am, Monday, 23'rd Mar 2026

The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.

Aurinia Announces Management Transition

08:00am, Monday, 23'rd Mar 2026

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Management Transition.

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

04:06pm, Thursday, 26'th Feb 2026

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript

03:28pm, Thursday, 26'th Feb 2026

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by